论文部分内容阅读
目的:探讨核酸适体KMF2-1a为基础的乳腺癌细胞靶向化疗药物载体的应用价值。方法:采用细胞仪检测人体乳腺癌MCF-1OAT1细胞内吞KMF2-1a的药物载体的作用,其结果以分光光度计检测。结果:核酸适体KMF2-1a及其药物载体可被MCF-1OAT1细胞特异性内吞。结论:核酸适体KMF2-1a可用于靶向治疗乳腺癌。
Objective: To investigate the value of KMF2-1a-based breast cancer cell targeted chemotherapeutic drug carrier. Methods: Cytometry was used to detect the drug carrier of endocytosis of KMF2-1a in human breast cancer MCF-1OAT1 cells. The results were analyzed by spectrophotometer. Results: The aptamer KMF2-1a and its drug carrier could be specifically endocytosed by MCF-1OAT1 cells. Conclusion: Aptamer KMF2-1a can be used to target breast cancer.